相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension Implications for Therapy
Benoit Lechartier et al.
CHEST (2022)
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy
Peter Kolkhof et al.
PHARMACOLOGICAL RESEARCH (2021)
Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells
Jessica Kowalski et al.
HYPERTENSION (2021)
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension
Divya P. Menon et al.
PULMONARY CIRCULATION (2021)
Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator
Alice Huertas et al.
CARDIOVASCULAR RESEARCH (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Mineralocorticoid receptor blockade improves pulmonary hypertension and right ventricular function in bronchopulmonary dysplasia: a case report
Roberto Giagnorio et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2020)
Spironolactone in pulmonary arterial hypertension: results of a cross-over study
Zeenat Safdar et al.
PULMONARY CIRCULATION (2020)
Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives
Marc Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
PKCδ Mediates Mineralocorticoid Receptor Activation by Angiotensin II to Modulate Smooth Muscle Cell Function
Qing Lu et al.
ENDOCRINOLOGY (2019)
Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity
Jana Grune et al.
HYPERTENSION (2018)
Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
Mario Boehm et al.
BMC PULMONARY MEDICINE (2018)
Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
Raquel Gonzalez-Blazquez et al.
FRONTIERS IN PHARMACOLOGY (2018)
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease Role of Oxidative Stress
Lionel Lattenist et al.
HYPERTENSION (2017)
Mineralocorticoid receptor antagonists: 60 years of research and development
Peter Kolkhof et al.
JOURNAL OF ENDOCRINOLOGY (2017)
Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension
Laurent Calvier et al.
HEART (2016)
Aldosterone-Induced Vascular Remodeling and Endothelial Dysfunction Require Functional Angiotensin Type 1a Receptors
Marie Briet et al.
HYPERTENSION (2016)
Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
Larbi Amazit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Paradoxical resistance to high-fat diet-induced obesity and altered macrophage polarization in mineralocorticoid receptor-overexpressing mice
Emmanuelle Kuhn et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Peter Kolkhof et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials)
Bradley A. Maron et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension
Ioana R. Preston et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2013)
Updated Clinical Classification of Pulmonary Hypertension
Gerald Simonneau et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Dysregulated Renin-Angiotensin-Aldosterone System Contributes to Pulmonary Arterial Hypertension
Frances S. de Man et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
Lars Baerfacker et al.
CHEMMEDCHEM (2012)
Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension
Bradley A. Maron et al.
CIRCULATION (2012)
Macrophage Mineralocorticoid Receptor Signaling Plays a Key Role in Aldosterone-Independent Cardiac Fibrosis
Laura A. Bienvenu et al.
ENDOCRINOLOGY (2012)
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
Bertram Pitt et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension
Ryutaro Yamanaka et al.
HYPERTENSION RESEARCH (2010)
Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation
K Ishizawa et al.
HYPERTENSION (2005)
Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells
LJ Min et al.
CIRCULATION RESEARCH (2005)
Mechanism for aldosterone potentiation of angiotensin II - Stimulated rat arterial smooth muscle cell proliferation
F Xiao et al.
HYPERTENSION (2004)
Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor
D Le Menuet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
